2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow

Shares are up ~15% YTD as J&J shifts focus after spinning off consumer health into Kenvue to prioritize innovative medicines and medtech. Stelara lost exclusivity but management says that headwind is largely 'in the rearview mirror' while the company now has 28 products/platforms generating ≥$1B each. J&J pays a $5.20 annual dividend (2.1% yield) and is a Dividend King, underpinning defensive income potential. Recommendation framed as buy-and-hold given portfolio diversification and steady free cash flow supporting continued dividend growth.

Analysis

JNJ’s strategic tilt toward higher-margin, innovation-led businesses creates a predictable flow of demand into a handful of specialist suppliers (CROs, CMOs, precision components for medtech) and makes small-cap device and biotech developers obvious M&A targets over the next 12–36 months. That reallocation of capital and procurement spending will compress unit economics for commodity suppliers while inflating multiples for scalable platform companies whose revenue is sticky and closely tied to procedure volumes.

The main near-term risks are idiosyncratic readouts and regulatory noise rather than macro cyclicality — a single adverse pivotal trial or a device recall would compress multiples sharply and could shave 10–20% off the stock in a matter of days. Over a 12–24 month horizon the bigger structural risks are pricing reforms and litigation tail events that can change free cash flow convertibility assumptions used by dividend-dependent investors.

From a positioning perspective, this is a classic “durable growth with optionality” trade: core long exposure for income and optional upside from M&A/pipeline re-rating, paired with cheap, time-limited hedges to manage binary clinical/regulatory outcomes. The market is likely underpricing the convexity that comes from recurring medtech consumables and software-enabled procedure capture; if procedure volumes re-accelerate, expect faster free cash flow expansion than current forward multiples imply.

Key Decisions for Investors

• Core long: Buy JNJ for a 3–5% portfolio weight, scale in on a 4–8% pullback; target 12–24 month total return of 15–30% (including dividends). Primary risks: single-trial failure or device recall — size to withstand a 10–15% drawdown without forced selling.
• Pairs trade (reduce market beta): Go long JNJ / short KVUE (equal notional) for 6–12 months to express premium on medtech/pharma optionality vs consumer cyclicality. Reward: asymmetric re-rating if JNJ delivers M&A/pipeline tailwinds; risk: consumer rebound or isolated JNJ adverse event — keep pair size to 1–2% net portfolio exposure.
• Options tactical (levered upside, capped loss): Buy a 9–12 month JNJ call spread — purchase ~5% out-of-the-money calls and sell ~20% out-of-the-money calls to finance — sized so max premium = 25% of intended equity exposure. Reward: 2–4x payoff if JNJ up ~20–30%; max loss = paid premium if thesis fails.
• Tail protection: Buy 6–12 month JNJ puts sized ~20% of long-equity exposure (or buy cheap deep-calendar puts) to protect against binary clinical/regulatory shocks. Cost is insurance; preserves optionality while limiting downside in the event of headline-driven sell-offs.